Can you imagine that FDA's demand for a complicated molecule such as Copaxone would be less (without bioequivalence) than for a simple compound such as aspirin? Thanks for your welcoming.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.